Patient leaflet - Nobilis OR Inac
B. PACKAGE LEAFLET
PACKAGE LEAFLET
Nobilis OR inac emulsion for injection for chickens
-
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE IN THE EEA
Marketing authorisation holder and manufacturer:
Intervet International
Wim de Korverstraat 35
5831 AN Boxmeer
The Netherlands
-
2. NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobilis OR inac emulsion for injection for chickens
-
3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Per dose of 0.25 ml:
Inactivated whole cell suspension of Ornithobacterium rhinotracheale serotype A strain B3263/91 1 × 10 cells
-
inducing a mean titre in the chickens of the potency test of at least 11.2 (log2).
Light liquid paraffin: 107.21 mg
Traces of formaldehyde
-
4. INDICATION(S)
For passive immunisation of broilers induced by active immunisation of female broiler breeders to reduce infection with Ornithobacterium rhinotracheale serotype A when this agent is involved. Under field conditions passive immunity is transferred during lay for 43 weeks after the last vaccination of broiler breeders, resulting in a duration of passive immunity in broilers of at least 14 days after hatching.
-
7. TARGET SPECIES
Chickens
-
8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Single dose of 0.25 ml.
Subcutaneous injection in the neck or intramuscular injection in the breast of the chicken.
-
9. ADVICE ON CORRECT ADMINISTRATION
Allow the vaccine to reach room temperature (15–25°C) before using the vaccine. Shake well before use. Use sterile vaccination equipment.
Vaccination scheme:
The vaccination scheme consists of two injections with a dose of 0.25 ml, administered subcutaneously in the neck or intramuscularly in the breast. The first injection can be administered at an age of 6 – 12 weeks. The second injection has to be administered at least 6 weeks later at an age of 14 – 18 weeks.
-
10. WITHDRAWAL PERIOD
Zero days
-
11. SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children.
Store and transport at 2 – 8°C.
Do not freeze.
Do not use after the expiry date stated on the label.
-
12. SPECIAL WARNING(S)
No information is available on the compatibility of this vaccine with any other. Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated.
To the user:
This product contains mineral oil. Accidental injection/self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you.
If pain persists for more than 12 hours after medical examination, seek medical advice again.
To the physician:
This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
No other undesirable effects have been observed after administration of a double dose when compared with a single dose of vaccine.
Occasionally hardened minor local swellings (0.5 – 2.0 cm) were observed which disappeared within 21 days after vaccination.
Do not mix with any other vaccine/immunological product.
-
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with the local requirements.
-
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
10.01.2008
-
15. OTHER INFORMATION